Full-Time

Lead Instrumentation and Electrical Technician

Deadline 8/3/27
WuXi AppTec

WuXi AppTec

1,001-5,000 employees

Global contract research, development, manufacturing organization

No salary listed

Middletown, DE, USA

In Person

Category
General Maintenance & Repair (1)
Required Skills
Microsoft Office
HVAC
GMP

Get referred to WuXi AppTec

See people who can refer or advise you

Requirements
  • A High School Diploma or GED is required.
  • At least 6 years of industrial or pharmaceutical maintenance experience is required; experience in electrical and instrumentation fields is preferred.
  • Demonstrated multi-craft troubleshooting ability involving pumps, motors, valves, air handlers, HVAC, boilers, and chillers is required.
  • Ability to interpret and work from a broad spectrum of drawing types is required.
  • Demonstrated understanding of cleanroom environments, strict gowning protocols, and documentation protocols is required.
  • Familiarity with process control systems, building automation systems, and environmental monitoring systems is required.
  • Basic proficiency with computer technologies and Microsoft Office is required.
  • Experience with modern data acquisition systems and historians and computerized maintenance management systems is required.
  • Ability to clearly and professionally communicate technical issues to non-technical stakeholders in person and electronically is required.
  • Ability to write technical subject matter for maintenance, facilities, and engineering staff is required.
  • Ability to work in a plant environment with variable noise levels, wear appropriate personal protective equipment including respirators, stand, sit, and walk for long periods, lift 50 pounds occasionally, maneuver in tight mechanical spaces, climb ladders, stairs, and scaffolding, work in boiler rooms, refrigerated storage, and outdoors, and distinguish color-coded wiring and piping is required.
Responsibilities
  • Utilize and manage the computerized maintenance management system.
  • Perform preventive, predictive, and corrective maintenance in coordination with production, Environment, Health and Safety, Facilities, and Engineering.
  • Perform routine and corrective maintenance on utilities equipment, including boilers, chillers, cooling towers, air compressors, process water systems, and generators.
  • Perform hands-on adjustments and repairs to instrumentation and electrical equipment to prevent product impact and downtime.
  • Provide on-site escort and technical supervision for specialized vendors.
  • Execute permitting procedures and coordinate daily maintenance and operational tasks.
  • Collaborate with utility and facility technical staff, process engineering, Environment, Health and Safety, Production, and third-party contractors to execute work orders.
  • Support client site visits and on-site audits by demonstrating technical mastery of processes and the environment.
  • Manage inventory of consumables, single-use assemblies, sensors, and filters required for planned and corrective maintenance.
  • Participate in operational procedures and cleaning and sanitization activities while adhering to current Good Manufacturing Practices.
  • Ensure maintenance activities comply with Environment, Health and Safety policies.
  • Identify and propose continuous improvements to equipment and workflows that improve yield, reduce ergonomic strain, and decrease setup time.
  • Execute and review documentation in real time while ensuring attributable, legible, contemporaneous, original, and accurate entries.
  • Act as the primary technical witness and subject matter expert for process deviation investigations, assist Quality Assurance with root cause analysis, and implement corrective actions.
  • Support validation protocols for new manufacturing technologies and equipment.
  • Maintain production suites in inspection-ready condition for FDA, DEA, internal, and client-led quality audits.
  • Lead the drafting and periodic review of standard operating procedures and drawings to reflect current Good Manufacturing Practices.
  • Retrieve logs and explain maintenance histories during regulatory audits.
  • Provide technical guidance and clear direction to maintenance personnel during assigned work activities, including safety and task prioritization.
  • Support safe work permitting and hazardous energy control procedures.
  • Provide technical training and mentoring to technician staff while performing hands-on maintenance activities.
  • Serve as the site's technical resource for instrumentation and electrical systems in preventive, predictive, and corrective maintenance.
  • Collaborate proactively with Production, Engineering, Quality, Environment, Health and Safety, and Facilities.
  • Foster a culture of right-first-time execution and continuous improvement.
  • Monitor and reduce waste of raw materials, consumables, and spare parts.
  • Support tracking of equipment effectiveness and provide feedback on bottlenecks, key performance indicators, and data collection techniques.
  • Suggest and implement cost-saving initiatives.
  • Support Environment, Health and Safety through participation in the site Emergency Response Program.
  • Participate in root cause analysis meetings to prevent recurrence of mechanical failures.
Desired Qualifications
  • Experience in electrical and instrumentation fields.
  • Journeyperson Electrical License.

What WuXi AppTec does: It provides a global, integrated open-access platform for contract research, development, and manufacturing services (CRDMO) to the pharmaceutical, biotechnology, and medical device industries. How its products work: Clients access a broad portfolio of capabilities—laboratory testing, process development, and manufacturing—across the full product lifecycle, from discovery and preclinical work to clinical and commercial production, often supported by strategic acquisitions to extend reach. How it differs from competitors: It combines extensive geographic reach with a wide, end-to-end service portfolio in one platform, rather than focusing on a narrow stage or region. What its goal is: To help innovators bring new medicines and healthcare products to market faster and with high quality.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Huangpu, China

Founded

2000

Get referred to WuXi AppTec

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • WuXi AppTec raised 2026 revenue guidance to RMB 58.5-60.5 billion on August 3, 2026.
  • H1 2026 revenue rose 38.9%, and backlog reached RMB 66.43 billion.
  • Delaware starts Q4 2026 and Singapore starts 2027, expanding non-China manufacturing capacity.

What critics are saying

  • On June 8, 2026, DoD added WuXi AppTec to the 1260H Chinese military list.
  • Customers terminated, paused, and redirected programs within weeks after the June 2026 designation.
  • If BIOSECURE targets WuXi in December 2026, U.S. business continuity faces existential damage.

What makes WuXi AppTec unique

  • WuXi AppTec’s integrated CRDMO spans discovery, development, and manufacturing across 30-plus countries.
  • Its 2026 capacity buildout covers Delaware, Singapore, Taixing, and Switzerland simultaneously.
  • DMPK compound management serves thousands of clients with one-million-plus compound storage and traceability.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
PR Newswire
Aug 3rd, 2026
WuXi AppTec H1 revenue surges 39% to $4B, raises 2026 guidance amid US defence list inclusion

WuXi AppTec reported strong first-half 2026 results and raised its full-year guidance. The Chinese pharmaceutical contract research, development, and manufacturing organisation posted H1 revenue of RMB 28.90 billion, up 38.9% year-on-year, with continuing operations revenue rising 48.0%. Adjusted non-IFRS net profit increased 83.2% to RMB 11.57 billion, whilst the gross profit margin expanded 9.4 percentage points to 53.9%. The company's backlog for continuing operations grew 25.2% to RMB 66.43 billion as of 30 June 2026. WuXi AppTec raised its 2026 total revenue target to RMB 58.5–60.5 billion, up from RMB 51.3–53.0 billion previously. The firm also increased its capital expenditure guidance to RMB 7.5–8.5 billion to support accelerated global capacity expansion. The company addressed its inclusion on the US Department of Defence's 1260H list, calling it erroneous and confirming legal action to protect stakeholder interests.

Associated Press
Jul 7th, 2026
WuXi AppTec launches automated compound management system with fourfold storage density and full traceability

WuXi AppTec DMPK has launched an automated compound management platform serving thousands of pharmaceutical and biotechnology companies worldwide, with storage capacity exceeding one million compounds. The system provides full lifecycle management through digital operations, featuring automated robotic retrieval, real-time weighing data integration with high-precision balances, and automated preparation via Hamilton systems. The platform addresses three major challenges in drug metabolism and pharmacokinetics research: diverse container types, large compound libraries, and strict storage requirements. Key capabilities include real-time logistics tracking, image recognition-based automated picking, and high-density mobile storage delivering approximately fourfold capacity versus fixed-cabinet layouts. The system maintains tamper-proof audit logs and role-based access control whilst integrating with the Mosaic Compound Management System. WuXi AppTec DMPK offers flexible managed services covering sample receipt, secure storage, distribution, and disposal, aiming to reduce operational costs and accelerate research timelines.

Associated Press
Jun 11th, 2026
WuXi AppTec expands peptide and oligonucleotide capacity, eyes 40% revenue growth in 2026

WuXi AppTec is expanding its global manufacturing capabilities for emerging drug modalities including peptides, oligonucleotides and targeted protein degraders, according to Pharma Manufacturing. The company's WuXi TIDES platform, focused on oligonucleotides and peptides, is projected to achieve approximately 40% year-on-year revenue growth in 2026. The company's solid-phase peptide synthesis reactor volume exceeded 100,000 litres at end-2025 and is expected to reach 130,000 litres by end-2026. New production facilities are under construction in Taixing, China, scheduled for 2027 operation, and Singapore, planned for 2028. WuXi AppTec is investing in process technologies combining solid-phase and liquid-phase synthesis to improve scalability for complex molecules. The company is also developing integrated approaches for antibody-drug conjugates and targeted protein degraders, incorporating earlier-stage chemistry and biology integration.

Yahoo Finance
Jun 9th, 2026
WuXi AppTec added to Pentagon's Chinese military list, vows to challenge 'erroneous designation

WuXi AppTec has been added to the Pentagon's list of "Chinese military companies", escalating tensions between the pharmaceutical manufacturer and the US. The Department of Defence updated its Section 1260H list on 8 June, adding WuXi alongside other Chinese firms including BYD and Comac. The DoD claims WuXi has links to China's State Administration for Science, Technology and Industry for National Defence and the People's Liberation Army. WuXi strongly denied the designation, calling it "clearly a mistake" and stating it is not owned, controlled or affiliated with any Chinese military or government entity. The contract research and manufacturing organisation, which operates in over 30 countries, reported revenues of $1.83 billion in Q1 2026, up 39.4% year-over-year. WuXi was previously removed from the BIOSECURE Act in October 2025.

Associated Press
Jun 5th, 2026
WuXi AppTec boosts capex 17% to $77M-$89M for global manufacturing expansion

WuXi AppTec is accelerating global manufacturing expansion across the United States, Europe and Asia, increasing capital expenditures by at least 17% this year to between RMB 6.5 billion and RMB 7.5 billion. The pharmaceutical contract research, development and manufacturing organisation is responding to growing customer demand, particularly for peptides and oligonucleotides. The company's new Middletown, Delaware facility will begin oral solid dosage manufacturing in Q4 2026, becoming its largest US site at 1.74 million square feet. In Europe, WuXi is expanding its Couvert, Switzerland site, whilst a Singapore facility is expected to begin Phase I operations in 2027. WuXi AppTec's small molecule pipeline reached 3,550 molecules by end-March 2026. Its TIDES business is projected to grow approximately 40% year-over-year.